Results 21 to 30 of about 24,117 (172)

Memantine-induced delayed sleep phase in Huntington’s disease: A case report

Clinical Parkinsonism & Related Disorders
Circadian rhythm sleep disorders may occur after memantine administration. We describe a 49-year-old woman with Huntington’s disease, who complained of sleep onset insomnia following the administration of memantine.
Youshi Fujita, Toshio Hamada, Satoshi Kubota, Tomomi Sakoh-Goshima, Hirotaka Shirasaki   +4 more
doaj   +2 more sources

Memantine-Derived Schiff Bases as Transdermal Prodrug Candidates

, 2022
Condensation reactions of salicylaldehyde, 2-pyridinecarboxaldehyde, and pyridoxaldehyde with memantine (Me) produced novel memantine-derived Schiff bases (1–3).
Renata Diniz (622538), Lucas A. M. Ferreira (12307153), Rafael P. Vieira (12307156), Jennifer T. J. Freitas (8414403), Ana P. Araujo de Oliveira (12307141), Clara M. da Cruz (12307147), Victoria C. Romero Colmenares (12307144), Eduardo B. Lages (12307150), Heloisa Beraldo (5462729)   +8 more
core   +3 more sources

Effect of memantine, an anti-Alzheimer’s drug, on rodent microglial cells in vitro

Scientific Reports, 2021
The pathophysiology of Alzheimer’s disease (AD) is related to neuroinflammatory responses mediated by microglia. Memantine, an antagonist of N-methyl-d-aspartate (NMDA) receptors used as an anti-Alzheimer’s drug, protects from neuronal death accompanied ...
Toru Murakawa-Hirachi, Yoshito Mizoguchi, Masahiro Ohgidani, Yoshinori Haraguchi, Akira Monji   +4 more
doaj   +1 more source

Donepezil and Memantine for moderate-to-severe Alzheimer's disease [PDF]

, 2012
Background Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease ...
Roy Jones (3539210), Juszczak, E, R. Brown (3682735), Gray, R, Richard Gray (2619970), Ballard, C, Burns, Alistair; id_orcid, Adams, Jessica, Knapp, M, J. Adams (7579901), Knapp, Martin, Robert Hills (3685870), Baldwin, A, P. Passmore (7608800), Dening, Tom, Griffin, M, S. Banerjee (1503751), B. Sheehan (7608761), Jones, Roy, T. Dening (7608776), Craig Ritchie (3531092), Sheehan, Bart, McShane, R, Mary Griffin (3203010), Bentham, Peter, O'Brien, John, Bart Sheehan (3836236), McShane, Rupert, Brown, R, Clive Holmes (237359), Dening, T, Hughes, Alan, Robin Jacoby (89610), Jones, R., Holmes, C, Clive Ballard (89605), Jacoby, Robin, Phillips, Patrick, Alan Hughes (178653), Sube Banerjee (4464202), D. Findlay (7608779), McKeith, I, Martin Knapp (146158), Ritchie, C. W., A. Baldwin (7608767), Ritchie, Craig, P. Phillips (5239541), Barber, R, C. Katona (6059216), David Findlay (46833), Banerjee, S, P. Bentham (7589273), Juszczak, Ed, Peter Bentham (16155026), Ashley Baldwin (14422653), Cornelius Katona (15210), Brown, Richard, J. Lindesay (7635890), McKeith, Ian, Barber, Robert, Brown, Richard; id_orcid, E. Juszczak (7589267), Burns, A, Banerjee, Sube, Macharouthu, Ajay, Edmund Juszczak (89612), Passmore, P, Jones, R, James Lindesay (7582160), Gray, Richard, Phillips, P, R. Jacoby (7589288), J. O'Brien (7608797), Robert Barber (337950), Phillips, P., A. Burns (842688), Tom Dening (3097692), R. Howard (1274091), Juszczak, Edmund, Ian McKeith (369422), Patrick Phillips (1420741), C. Holmes (7589285), Peter Passmore (254593), M. Griffin (3933326), Macharouthu, A, M. Knapp (2534038), Rupert McShane (89609), C. Ballard (7608770), Passmore, Peter, Johnson, T, R. l. Barber (7635893), Robert Howard (190740), Hills, Robert Kerrin, Findlay, David, Jacoby, R, Johnson, T., Hughes, A., Barber, R., Howard, Robert, Jessica Adams (2640001), Jones, Roy W., O'Brien, J. T., R. McShane (7608791), Howard, R, Holmes, Clive, Katona, C, Lindesay, J, I. McKeith (7608788), Ritchie, C, Adams, J., A. Macharouthu (7608794), T. Johnson (7602368), Johnson, Tony, McKeith, I. G., A. Hughes (7190519), Jones, Rob, Caroline Onions (16155023), Katona, C. L. E., R. Hills (7635896), John O'Brien (377563), Hills, Robert, Hughes, A, Lindesay, James, Hills, R, Rob Jones (3023226), Tony Johnson (1947625), Onions, Caroline, Griffin, Mary, C. Ritchie (7608806), Onions, C, Richard Brown (130157), Katona, Cornelius, Baldwin, Ashley, Sheehan, B, Adams, J, Burns, Alistair, Burns, Alistair S., Griffin, M., R. Jones (3979994), Ballard, Clive, C. Onions (7608764), Alistair Burns (3580904), Findlay, D, O'Brien, J, Bentham, P, R. Gray (7608782), Ajay Macharouthu (6553472)   +146 more
core   +1 more source

Deep Brain Stimulation Reduces Conflict‐Related Theta and Error‐Related Negativity in Patients With Obsessive–Compulsive Disorder

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Objectives Obsessive–compulsive disorder (OCD) is a psychiatric disorder with alterations of cortico‐striato‐thalamo‐cortical loops and impaired performance monitoring. Electrophysiological markers such as conflict‐related medial frontal theta (MFT) and error‐related negativity (ERN) may be altered by clinically effective deep brain ...
Elena Sildatke, Theo O. J. Gruendler, Markus Ullsperger, Till A. Dembek, Juan Carlos Baldermann, Sina Kohl, Veerle Visser‐Vandewalle, Daniel Huys, Jens Kuhn, Thomas Schüller   +9 more
wiley   +1 more source

A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa® Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer’s Disease Already Receiving Donepezil (ROMEO-AD)

Neurology and Therapy, 2023
Introduction This multicentre, randomised, open-label, and prospective study aimed to evaluate the effectiveness of memantine (memantine solution) on speech function in patients with moderate to severe Alzheimer’s disease (AD) who were already on ...
Hee-Jin Kim, YongSoo Shim, Hyun Jeong Han, Byeong C. Kim, Kee Hyung Park, So Young Moon, Seong Hye Choi, Dong Won Yang, Bora Yoon, Eun-Joo Kim, Jee Hyang Jeong, Seol-Heui Han   +11 more
doaj   +1 more source

Memantine Disrupts Motor Coordination through Anxiety-like Behavior in CD1 Mice

Brain Sciences, 2022
Memantine is an FDA approved drug for the treatment of Alzheimer’s disease. It reduces neurodegeneration in the hippocampus and cerebral cortex through the inhibition of extrasynaptic NMDA receptors in patients and mouse models.
Anton N. Shuvaev, Olga S. Belozor, Oleg I. Mozhei, Aleksandra G. Mileiko, Ludmila D. Mosina, Irina V. Laletina, Ilia G. Mikhailov, Yana V. Fritsler, Andrey N. Shuvaev, Anja G. Teschemacher, Sergey Kasparov   +10 more
doaj   +1 more source

Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal–CA1 projection

BMC Neuroscience, 2021
Background Memantine, a low- to moderate-affinity uncompetitive N-methyl-D-aspartate receptor antagonist, has been shown to improve cognitive functions in animal models of Alzheimer’s disease (AD).
Peng Li, Jin Xu, Huanhuan Gu, Hua Peng, You Yin, Jianhua Zhuang   +5 more
doaj   +1 more source

Contribution of Lysosome and Sigma Receptors to Neuroprotective Effects of Memantine Against Beta-Amyloid in the SH-SY5Y Cells [PDF]

Advanced Pharmaceutical Bulletin, 2020
Purpose: Memantine is an approved drug for the treatment of Alzheimer’s disease (AD). Autophagy, lysosome dysfunction, and sigma receptors have possible roles in the pathophysiology of AD.
Mojtaba Keshavarz, Majid Reza Farrokhi, Elahe Amirinezhad Fard, Mohammad Mehdipour   +3 more
doaj   +1 more source

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. [PDF]

, 2012
BACKGROUND: Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK.
G Rogers, T Moxham, P Thokala, Hoyle, M, Peters, J, Wailoo, Allan, M Bond, Rogers, G, C Hyde, Bond, M, Rogers, G; id_orcid, Wailoo, A, M Hoyle, A Wailoo, Thokala, P, Moxham, T, A Miners, M Jeffreys, Miners, A, R Anderson, Anderson, R, Hyde, C, Davis, S, J Peters, S Davis, Jeffreys, M   +25 more
core   +1 more source